Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (249)	3/18/2005 4:24:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Possible reason for INGN weakness today? You mean besides persistent short selling ? <g> But don't worry, it seems they will have to cover some of that next month. (The short position reportedly is around 28% of the float. Insiders hold more than 30% ) I always liked INGN241's potential more than ADVEXIN's and also liked the: "Concluding Perspective on mda-7/IL-24: a Gene with a Potentially Bright Future" On the link provided by Tuck. RAGL Bernard